China, Beijing
Hu Kai
Beijing GoBroad Boren Hospital utilizes on-site CAR-T cell production, eliminating shipping delays and ensuring personalized treatment. Dr. Hu Kai, a member of the First China T-cell lymphoma Working Group, leads a sequential strategy with tumor-reducing therapy before infusion. The package costs around $100,000 and spans 5-6 weeks, including complete diagnostics, cell preparation, infusion, and single-room hospital accommodation at the Beijing GoBroad Boren Hospital. This national leader in CAR-T therapy has performed over 4,000 treatments, maintaining a comprehensive system to manage potential side effects.